E Europe briefs: Serbia to raise prices of 400 drugs; SANEVIT privatization
The Serbian Ministry of Health will raise the prices of more than 400 Drugs once a new government is formed. In doing so, the Ministry aims to overcome the long-standing problem of drug shortages in Serbia, writes Sebastian Gensior in the Europe-health-care.eu news service.
Based on presented needs of the Serbian health care institutions and data about missing drugs, it has been determined that there is an urgent need for changing the prices of drugs containing the five most used active ingredients: methyldopa(antihypertensive), furosemide (for heart failure), aminophylline (for asthma) and ranitidine(for hives). Given the identified shortages, the Ministry of Health proposed to increase the prices of those drugs in order to secure constant procurement of these drugs.
Romanian syringe producer SANEVIT will be privatized
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze